DDInter1123 DDInter1220
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chies
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible proposal that noradrenaline plays an important role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease .
Mannitol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Milnacipran
Mannitol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} (Compound) resembles {v} (Compound) Milnacipran
Mannitol {u} (Compound) resembles {v} (Compound) Calcium glucoheptonate
Calcium glucoheptonate {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Milnacipran
Mannitol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Mannitol {u} (Compound) causes {v} (Side Effect) Urinary retention
Urinary retention {u} (Side Effect) is caused by {v} (Compound) Meperidine
Meperidine {u} (Compound) resembles {v} (Compound) Milnacipran
Mannitol {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Clopidogrel
Clopidogrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dipyridamole
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Mannitol {u} (Compound) palliates {v} (Disease) glaucoma
glaucoma {u} (Disease) is palliated by {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} (Compound) resembles {v} (Compound) Milnacipran
Mannitol {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Milnacipran
Mannitol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Milnacipran (Compound)
Mannitol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Mannitol (Compound) resembles Calcium glucoheptonate (Compound) and Calcium glucoheptonate (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Milnacipran (Compound)
Mannitol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Mannitol (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Meperidine (Compound) and Meperidine (Compound) resembles Milnacipran (Compound)
Mannitol (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Clopidogrel (Compound) and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dipyridamole (Compound) and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Mannitol (Compound) palliates glaucoma (Disease) and glaucoma (Disease) is palliated by Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Mannitol (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Milnacipran